Why the study?
Does long-term outpatient dalteparin provide effective and safe secondary prevention in patients with prothrombotic disorders who failed or are unsuitable for warfarin?
Does long-term outpatient dalteparin provide effective and safe secondary prevention in patients with prothrombotic disorders who failed or are unsuitable for warfarin?
Answers are grounded in this paper and cite their sources.
Long-term outpatient dalteparin appears effective and safe for secondary prevention of thrombosis in patients who have failed or are unsuitable for warfarin therapy.
The availability of low molecular weight heparin (LMWH), with associated ease of home delivery and enhanced efficacy and safety, has rendered the long-term outpatient use of LMWH feasible. Although warfarin is usually used for long-term secondary prevention, it is not the drug of choice for a variety of conditions such as antiphospholipid thrombosis syndrome, sticky platelet syndrome, and patients with malignancy and other medical conditions who have failed adequate warfarin doses. We assessed the long-term efficacy and safety of outpatient dalteparin in a series of patients with conditions associated with prior warfarin failure or potential to warfarin therapy (antiphospholipid syndrome). The results of this study, detailed herein, demonstrate that long-term dalteparin is highly effective and safe when used as long-term therapy for secondary prevention in selected prothrombotic disorders.
No takes yet. Share an insight, caveat, or question.
Bick et al. (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: